The impact of genomics on drug discovery

Annual Review of Pharmacology and Toxicology

Volumn 40, Issue , 2000, Pages 193-208

  Debouck, G ^a   Metcalf, B ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cathepsin K; EST; G protein coupled receptors; Microarrays; Proteomics

Indexed keywords

DRUG;

DRUG INDUSTRY; DRUG RESEARCH; GENE SEQUENCE; GENE TECHNOLOGY; GENE THERAPY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CATHEPSINS; DRUG INDUSTRY; EXPRESSED SEQUENCE TAGS; GENE LIBRARY; GENOME; GTP-BINDING PROTEINS; HUMANS; RECEPTORS, CELL SURFACE;

EID: 17544377194     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.40.1.193     Document Type: Review

References (15)

1. Adams MD, Kelley JM, Gocayne JD, Dubnick M, Polymeropoulos MH, et al. 1991. Complementary DNA sequencing: expressed sequence tags and human genome project. Science 252:1651-56
2. Pandey A, Lewitter F. 1999. Nucleotide sequence databases: a gold mine for biologists. Trends Biochem. Sci. 24:276-80
3. Karp PD, Krummenacker M, Paley S, Wagg J. 1999. Integrated pathwaygenome databases and their role in drug discovery. Trends Biotechnol. 17:275-81
4. Hillier LD, Lennon G, Becker M, Bonaldo MF, Chiapelli B, et al. 1996. Generation and analysis of 280,000 human expressed sequence tags. Genome Res. 6:807-28
5. James IE, Walsh S, Dodds RA, Gowen M. 1991. Production and characterization of osteoclast-selective monoclonal antibodies that distinguish between multinucleated cells derived from different human tissues. J Histochem. Cytochem. 39:905-14
6. Drake FH, Dodds R, James I, Connor J, Debouck C, et al. 1996. Cathepsin K but not cathepsins B, L or S is abundantly expressed in human osteoclasts. J. Biol. Chem. 271:12511-16
7. Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, et al. 1996. Proteolytic activity of human osteoclast cathepsin K: expression, purification, activation and substrate identification. J. Biol. Chem. 271:12517-24
8. Gelb BD, Shi G-P, Chapman HA, Desnick RJ. 1996. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-38
9. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, et al. 1998. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 95:13453-58
10. Gowen M, Lazner F, Dodds R, Field J, Tavaria M, et al. 1999. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. In press.
11. Zhao B, Janson C, Amegadzie B, D'Alessio K, Griffin C, et al. 1997. Crystal structure of human osteoclast cathep sin K complex with E64. Nat. Struct. Biol. 4:109-11
12. Yamashita DS, Smith WW, Zhao B, Janson CA, Tomaszek TA, et al. 1997. Structure and design of potent and selective cathepsin K inhibitors. J. Am. Chem. Soc. 119:11351-52
13. Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, et al. 1997. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Miner. Res. 12:1396-406
14. Kensler TW, Mutter G, Hankerson JG, Reck LJ, Harley C, et al. 1981. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 41:894-904
15. Shapiro DJ, Rodwell VW. 1971. Regulation of hepatic 3-hydroxy-3-methyl-glutaryl coenzyme A reductase and cholesterol synthesis. J. Biol. Chem. 246: 3210-16